Citigroup
LUMO

Citigroup’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Citigroup’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$12K – 6462
2021
Q1 		$12K Buy
+1,000
New +$16.8K ﹤0.01% 5564
2019
Q4 		– Sell
-365
Closed -$5K – 7833
2019
Q3 		$5K Sell
365
-311
-46% -$4.56K ﹤0.01% 7355
2019
Q2 		$9K Sell
676
-254
-27% -$3.84K ﹤0.01% 7348
2019
Q1 		$16K Sell
930
-715
-43% -$10.7K ﹤0.01% 7071
2018
Q4 		$23K Sell
1,645
-1,818
-52% -$32K ﹤0.01% 6818
2018
Q3 		$75K Buy
3,463
+1,652
+91% +$50.2K ﹤0.01% 6176
2018
Q2 		$78K Buy
1,811
+1,472
+434% +$67.4K ﹤0.01% 5933
2018
Q1 		$22K Buy
339
+312
+1,156% +$22.1K ﹤0.01% 6706
2017
Q4 		$2K Sell
27
-241
-90% -$19.9K ﹤0.01% 7412
2017
Q3 		$25K Sell
268
-395
-60% -$30.3K ﹤0.01% 6368
2017
Q2 		$44K Sell
663
-2,983
-82% -$369K ﹤0.01% 5882
2017
Q1 		$791K Buy
3,646
+566
+18% +$80.9K ﹤0.01% 3459
2016
Q4 		$285K Buy
3,080
+1,611
+110% +$182K ﹤0.01% 4983
2016
Q3 		$198K Sell
1,469
-993
-40% -$98.6K ﹤0.01% 4664
2016
Q2 		$250K Sell
2,462
-3,383
-58% -$419K ﹤0.01% 4296
2016
Q1 		$958K Buy
5,845
+4,195
+254% +$850K ﹤0.01% 3392
2015
Q4 		$541K Sell
1,650
-952
-37% -$310K ﹤0.01% 3770
2015
Q3 		$839K Buy
2,602
+745
+40% +$327K ﹤0.01% 3271
2015
Q2 		$739K Buy
1,857
+815
+78% +$346K ﹤0.01% 3369
2015
Q1 		$514K Sell
1,042
-152
-13% -$58.9K ﹤0.01% 3720
2014
Q4 		$427K Buy
1,194
+909
+319% +$271K ﹤0.01% 4025
2014
Q3 		$55K Sell
285
-142
-33% -$31.2K ﹤0.01% 5252
2014
Q2 		$102K Sell
427
-323
-43% -$65.7K ﹤0.01% 4655
2014
Q1 		$191K Sell
750
-458
-38% -$140K ﹤0.01% 4375
2013
Q4 		$239K Buy
1,208
+659
+120% +$117K ﹤0.01% 4498
2013
Q3 		$93K Buy
549
+545
+13,625% +$87.7K ﹤0.01% 4787
2013
Q2 		$0 Buy
+4
New +$566 ﹤0.01% 6806

Other funds holding LUMO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's LUMO Position: Q2 2021 in Review

Citigroup sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2021, closing a stake of 1,000 shares — an estimated $12K sold.

Citigroup first reported a position in LUMO in Q2 2013 and held it in 27 quarters. The position peaked at $958K in Q1 2016. 40 funds tracked by Wall St. Rank hold LUMO as of Q2 2021.

  • Citigroup reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Citigroup sold 1,000 Lumos Pharma, Inc. Common Stock shares in Q2 2021, an estimated $12K.
  • Citigroup first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Citigroup's Lumos Pharma, Inc. Common Stock position peaked at $958K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.